AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
icotinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| tyrosine kinase inhibitors | 5209 | 610798-31-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Icotinib is a new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that developed and used in China for the treatment of patients with non-small cell lung cancer (NSCLC).
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.098 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.658 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 55.976 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 21.878 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 8.010 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 27 | % | High | 1 |
| herg | hERG pIC50 | 5.059 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 5.395 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 37.844 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 4.110 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT3,ALK,AURKA,AURKB,AXL,BLK,BMX,BRAF,CAMK2B,CAMK2D,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,ERBB4,FLT3,FYN,IRAK1,IRAK3,ITK,JAK1,KDR,KIT,LYN,MAP3K1,MAP3K10,MAP3K21,MAP4K1,MAP4K3,MAP4K5,MAPK10,MAPK7,MAPKAPK2,MARK4,MET,MKNK1,MKNK2,MTOR,NTRK1,PDK1,PDK2,PDK4,PIK3CG,PRKCD,PRKDC,SIK2,SIK3,STK10,STK33,SYK,TEK,TTK,ULK1,YES1 | 61 | |||
| kinase-selectivity-class | AURKA,BRAF,CAMK2D,DDR1,EGFR,ERBB2,ERBB4,MAP3K21,MAPK7,PDK4,PRKDC | 11 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 3.990 | High | 1 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 5 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 50.003 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 7.910 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 8.356 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 13.280 | % | High | 1 |
| rat-kpuu-brain | Rat brain Kpuu | 0.125 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 45.082 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 52.590 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 6.050 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 5.508 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | China Food and Drug Administration (CFDA) | Zhejiang Beta Pharma Inc. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01EB08 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
Related Drugs by ATC class:
L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Non-small cell lung cancer | indication | 254637007 | DOID:3908 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.01 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Epidermal growth factor receptor | Kinase | INHIBITOR | IC50 | 8.70 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Cyclin-G-associated kinase | Kinase | Kd | 6.14 | CHEMBL | |||||
| Receptor-interacting serine/threonine-protein kinase 2 | Kinase | Kd | 5.58 | CHEMBL | |||||
| STE20-like serine/threonine-protein kinase | Kinase | Kd | 5.98 | CHEMBL | |||||
| Serine/threonine-protein kinase 10 | Kinase | Kd | 6.64 | CHEMBL | |||||
| Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma | Kinase | Kd | 5.33 | CHEMBL | |||||
| Mitotic checkpoint serine/threonine-protein kinase BUB1 | Kinase | Kd | 5.54 | CHEMBL | |||||
| Cysteine--tRNA ligase, cytoplasmic | Enzyme | Kd | 6.19 | CHEMBL | |||||
| Mitogen-activated protein kinase kinase kinase 1 | Kinase | Kd | 5.38 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 9G6U5L461Q | UNII |
| 1204313-51-8 | SECONDARY_CAS_RN |
| C2604307 | UMLSCUI |
| CHEBI:750435 | CHEBI |
| CHEMBL2087361 | ChEMBL_ID |
| 22024915 | PUBCHEM_CID |
| DB11737 | DRUGBANK_ID |
| CHEMBL4297665 | ChEMBL_ID |
| C531470 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7641 | IUPHAR_LIGAND_ID |
| A1CI6 | PDB_CHEM_ID |
| 9G6U5L461Q | INXIGHT DRUGS |
Pharmaceutical products:
None